What is the role of plasma and tissue transglutaminases in the pathophysiology of factor XIII (FXIII) deficiency?

Updated: Aug 01, 2019
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Perumal Thiagarajan, MD  more...
  • Print

Plasma and tissue transglutaminases have been reported to promote cell adhesion through specific integrins for 2 different tumor cell types, MOLT-3 human lymphocyte–like leukemia and melanoma cells and SW480 colon cancer cells transfected with a ligand. [59] In contrast, FXIII did not stimulate growth of cultured human tumor cells. [60] An intriguing observation is the potential use of subunit A of FXIII and FXIII activity as a tumor marker in malignant brain tumors; its presence may distinguish benign from malignant brain tumors. [61] Recently, it was shown for the first time that intranuclear accumulation and cross-linking activity of FXIIIa occurred in maturing monocytes, supporting the hypothesis that FXIIIa may be involved in cell proliferation/differentiation, chromatin structure remodeling, and even cell death. [62] Further data are needed to unravel the role of FXIII in malignancies.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!